Trial Profile

Phase III clinical trial to investigate the treatment of Long COVID/Post-Acute Sequelae of COVID (PASC) with Selzentry (maraviroc) and Lipitor (atorvastatin) tablets

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2025 New trial record
12 Feb 2025 According to the HealthBio Therapeutics media release, In February 2024, HealthBio announced acceptance by the Food and Drug Administration (FDA) to proceed with the clinical trial to support a New Drug Application (NDA) filing through the Fast-Track 505(B)(2) pathway of the Federal Food, Drug, and Cosmetic Act (FDCA).
12 Feb 2025 According to the HealthBio Therapeutics media release, Patients can pre-enroll in this clinical trial, which is set to begin in March 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com